Hypercholesterolemia
Conditions
Keywords
Multi-Center Survey, patients currently on lipid-lowering pharmacological treatment, level of Control of Hypercholesterolemia in Egypt
Brief summary
Study objective is to evaluate the level of control of hypercholesterolemia in Egypt in patients taking lipid lowering agents for at least 3 months ( with no drug change or dose amendment for a minimum of 6 weeks).
Detailed description
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Interventions
None listed
Sponsors
AstraZeneca
Study design
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years and above on current lipid lowering drug for at least 3 months with no dose change for a minimum of 6 weeks * Subject must provide informed consent and comply with the survey procedures
Exclusion criteria
* Less than 18 years less than 3 months on antidyslipidemic agent Subjects who are unwilling or unable to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , overall and by country | 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , in the following sub-populations: - primary/secondary prevention patients and with metabolic syndromes | 24 weeks |
| The proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the Third Joint European Task Force guideline, in the following sub-populations: - primary/secondary prevention patients and with metabolic syndromes | 24 weeks |
| Determinants (e.g. patient and physician characteristics , country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia | 24 weeks |
| Physician characteristics associated with the allocation of treatment regimen. | 24 weeks |
| The proportion of patients on lipid-lowering treatment reaching the non HDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III , in the sub-population patients with fasting triglycerides<200 mg/d | 24 weeks |
Outcome results
None listed